These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7650691

  • 1. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
    Dezube M, Sugg EE, Birkemo LS, Croom DK, Dougherty RW, Ervin GN, Grizzle MK, James MK, Johnson MF, Mosher JT.
    J Med Chem; 1995 Aug 18; 38(17):3384-90. PubMed ID: 7650691
    [Abstract] [Full Text] [Related]

  • 2. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
    Sugg EE, Kimery MJ, Ding JM, Kenakin DC, Miller LJ, Queen KL, Rimele TJ.
    J Med Chem; 1995 Jan 06; 38(1):207-11. PubMed ID: 7837233
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
    Hirst GC, Aquino C, Birkemo L, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Henke B, James MK, Johnson MF, Momtahen T, Queen KL, Sherrill RG, Szewczyk J, Willson TM, Sugg EE.
    J Med Chem; 1996 Dec 20; 39(26):5236-45. PubMed ID: 8978852
    [Abstract] [Full Text] [Related]

  • 4. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE.
    J Med Chem; 1996 Jan 19; 39(2):562-9. PubMed ID: 8558528
    [Abstract] [Full Text] [Related]

  • 5. Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors.
    Shiosaki K, Lin CW, Kopecka H, Bianchi B, Miller T, Stashko M, Witte D.
    J Med Chem; 1997 Mar 28; 40(7):1169-72. PubMed ID: 9089338
    [Abstract] [Full Text] [Related]

  • 6. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH, Blommaert AG, Moizo L, Bado A, Ducos B, Böhme A, Garbay C, Roques BP.
    Bioorg Med Chem; 1996 Apr 28; 4(4):563-73. PubMed ID: 8735845
    [Abstract] [Full Text] [Related]

  • 7. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
    Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ, Hill D.
    J Med Chem; 1998 Jan 01; 41(1):38-45. PubMed ID: 9438020
    [Abstract] [Full Text] [Related]

  • 8. Characterization of novel peptoid agonists for the CCK-A receptor.
    Hughes J, Dockray GJ, Hill D, Garcia L, Pritchard MC, Forster E, Toescu E, Woodruff G, Horwell DC.
    Regul Pept; 1996 Aug 27; 65(1):15-21. PubMed ID: 8876031
    [Abstract] [Full Text] [Related]

  • 9. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW, Holladay MW, Barrett RW, Wolfram CA, Miller TR, Witte D, Kerwin JF, Wagenaar F, Nadzan AM.
    Mol Pharmacol; 1989 Dec 27; 36(6):881-6. PubMed ID: 2601685
    [Abstract] [Full Text] [Related]

  • 10. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ, Weng JH, Ducos B, Durieux C, Boudeau P, Bohme A, Roques BP.
    J Med Chem; 1993 Jan 08; 36(1):166-72. PubMed ID: 8421283
    [Abstract] [Full Text] [Related]

  • 11. Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.
    Elliott RL, Kopecka H, Bennett MJ, Shue YK, Craig R, Lin CW, Bianchi BR, Miller TR, Witte DG, Stashko MA.
    J Med Chem; 1994 Jan 21; 37(2):309-13. PubMed ID: 8295219
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M, Rodriguez M, Lignon MF, Galas MC, Bernad N, Artis-Noël AM, Hauad L, Laur J, Califano JC, Aumelas A.
    J Med Chem; 1993 Oct 01; 36(20):3021-8. PubMed ID: 7692048
    [Abstract] [Full Text] [Related]

  • 13. The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor.
    Dunlop J, Pass I, Ennis C.
    Neuropeptides; 1998 Apr 01; 32(2):157-60. PubMed ID: 9639254
    [Abstract] [Full Text] [Related]

  • 14. Modification of "peptoid" CCK-B antagonists to probe requirements for CCK-B agonist activity.
    Davey AE, Horwell DC.
    Bioorg Med Chem; 1993 Jul 01; 1(1):45-58. PubMed ID: 8081837
    [Abstract] [Full Text] [Related]

  • 15. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F, Nadzan AM.
    Mol Pharmacol; 1991 Mar 01; 39(3):346-51. PubMed ID: 1706470
    [Abstract] [Full Text] [Related]

  • 16. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
    de Tullio P, Delarge J, Pirotte B.
    Curr Med Chem; 1999 Jun 01; 6(6):433-55. PubMed ID: 10213792
    [Abstract] [Full Text] [Related]

  • 17. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG, Dhôtel H, Ducos B, Durieux C, Goudreau N, Bado A, Garbay C, Roques BP.
    J Med Chem; 1997 Feb 28; 40(5):647-58. PubMed ID: 9057851
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
    Bellier B, McCort-Tranchepain I, Ducos B, Danascimento S, Meudal H, Noble F, Garbay C, Roques BP.
    J Med Chem; 1997 Nov 21; 40(24):3947-56. PubMed ID: 9397175
    [Abstract] [Full Text] [Related]

  • 19. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
    Beinborn M, Chen C, DeMeo L, McBride EW, Kopin AS.
    Yale J Biol Med; 1998 Nov 21; 71(3-4):337-46. PubMed ID: 10461364
    [Abstract] [Full Text] [Related]

  • 20. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea]: an irreversible cholecystokinin type-B receptor antagonist.
    Dunlop J, Brammer N, Evans N, Ennis C.
    Biochem Pharmacol; 1997 Jul 01; 54(1):81-5. PubMed ID: 9296353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.